NCT07252479 2026-02-11Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS MutationsAdlai Nortye Biopharma Co., Ltd.Phase 1 Recruiting91 enrolled